AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Jazz Pharmaceuticals to present 19 abstracts at SLEEP 2025 conference.
ByAinvest
Thursday, May 29, 2025 7:32 am ET1min read
• Jazz Pharmaceuticals to present 19 abstracts at SLEEP 2025 • 11 late-breaking abstracts showcase sleep medicine research • Phase 4 data evaluates Xywav effectiveness in narcolepsy and IH • First interim results from XYLO trial to be presented • Extensive research highlights Jazz's leadership in sleep medicine • Ongoing commitment to advancing narcolepsy and IH treatment • Abstracts to be presented at the Associated Professional Sleep Societies meeting
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present a total of 19 abstracts at the SLEEP 2025 meeting, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), scheduled from June 8-11, 2025, in Seattle. Among these, 11 are late-breaking abstracts that highlight the company's extensive research in sleep medicine, particularly in the treatment of narcolepsy and idiopathic hypersomnia (IH).The abstracts will showcase Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, in patients with narcolepsy and IH. Highlights include the first interim results from the open-label, single arm XYLO trial, which assesses ambulatory and office blood pressure changes in narcolepsy patients after switching from a twice-nightly high-sodium oxybate oral solution to low-sodium oxybate, Xywav. Additionally, the DUET trial will present novel results on multiple sleep parameters, including the first presentation of polysomnography (PSG) outcomes in adults with IH.
Jazz Pharmaceuticals' commitment to patient-centric care is evident in these presentations, which aim to advance the understanding and treatment of narcolepsy and IH. The company's leadership in sleep medicine is underscored by the extensive research being presented at SLEEP 2025. The abstracts are available online at sleepmeeting.org/abstract-supplements [1].
References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-expansive-research-demonstrating-comprehensive-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-in-sleep-conditions-and-associated-comorbidities-at-sleep-2025-302467729.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet